Hims & Hers Touts AI Personalization in Strong Earnings

Hims & Hers' AI strategy centers on its MedMatch technology, which analyzes millions of anonymized data points from patient visits to recommend optimal treatments. Initially deployed for anxiety and depression, the system helps providers select medication, dosage, and form factor, with plans to expand into new categories like low testosterone and menopause. The company's Q4 2025 revenue grew 28% year-over-year to $617.8 million, with a subscriber base exceeding 2.5 million. Full-year 2025 revenue jumped 59% to $2.35 billion, driven by both its established men's health services and significant expansion in international markets. For consumer health startups, integrating with wearable APIs is key for personalization, with Apple HealthKit, Google Fit, Garmin, Oura, and Fitbit being the most common choices for developers. While native SDKs require platform-specific development, unified API platforms are emerging to streamline access to standardized health data from multiple devices, cutting development time from months to weeks. Navigating data privacy is critical, as consumer-facing wellness apps that collect data directly from users often fall outside of HIPAA's scope. However, new state-level regulations like Washington's "My Health My Data Act" are creating stricter rules, requiring explicit opt-in consent before collecting or sharing any consumer health information. Building user trust hinges on transparent data handling, clear consent flows, and robust security. Successful platforms avoid legal jargon, give users granular control over their data, and humanize the experience with conversational language, which is crucial for communities discussing sensitive topics like chronic illness or parental health. Early-stage digital health fundraising is increasingly focused on startups in TechBio, Health Management Solutions, and Medical Diagnostics. Venture firms like Rock Health, Khosla Ventures, and Andreessen Horowitz are key players, and demonstrating early traction with a clear, scalable delivery model is crucial for securing seed-stage capital. The longevity and biohacking space, a key adjacent market, is seeing massive investment in startups focused on extending healthspan. Companies like Altos Labs and BioAge Labs are pioneering cellular rejuvenation and using AI for aging-related drug discovery, reflecting a broader consumer trend toward proactive, data-driven health optimization.